Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
This trial is active, not recruiting.
|Sponsor||Institute of Oncology Ljubljana|
|Start date||February 2007|
|End date||April 2009|
|Trial size||43 participants|
|Trial identifier||NCT00689702, EMR 62202-688|
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced primary resectable rectal cancers.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Complete pathological remission rate
time frame: at pathological examm of surgical speciment
Rate of sphincter sparing surgical procedure Toxicity/safety
time frame: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
Male or female participants from 18 years up to 80 years old.
Inclusion Criteria: - Age 18 to 80 if judged fit for surgery - WHO performance status 0-1 - Histologically proven rectal adenocarcinoma located below the peritoneum - T3-T4 or/and nodal involvement determined by rectal ultrasound or computed tomography (CT) or MRI - No distant metastases - Adequate haematological, cardiac, liver and renal function - Signed informed consent - Appropriate measures for contraception for men and women, if applicable Exclusion Criteria: - Prior radio- and/or chemotherapy - Others synchronous cancers - History of other malignant disease - Significant heart disease - Known hypersensitivity to biological drugs - Pregnant or lactating patient
|Official title||Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study|
|Principal investigator||Vaneja Velenik, PhD, MD|
|Description||Preoperative radiotherapy and 5-FU based chemotherapy, along with the complete resection of the mesorectum is a standard treatment of locally advanced rectal cancer.Capecitabine has the potential to replace 5-FU as standard agent. Cetuximab is a monoclonal antibody directed against EGFR. Both agents are active in treatment of colorectal cancer and have demonstrated radiosensitising properties.The trial aims to assess the efficacy, safety and toxicity of the combination of cetuximab, capecitabine and radiation in patients with stage II and III rectal cancer.|
Call for more information